☆ 4.3 Article

Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives

CURRENT MEDICAL SCIENCE (2022)

Related references

Note: Only part of the references are listed.

Article Endocrinology & Metabolism

Overview of the 2022 WHO Classification of Pituitary Tumors

Sylvia L. Asa et al.

Summary: This review summarizes the changes in the 5th Edition of the WHO Classification of Endocrine and Neuroendocrine Tumors related to the pituitary gland, including the classification of pituitary lobe tumors and the detailed subtyping based on tumor cell lineage, cell type, and characteristics.

ENDOCRINE PATHOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

MicroRNAs in Dopamine Agonist-Resistant Prolactinoma

Xueyan Wan et al.

Summary: Abnormal miRNA expression plays a key role in dopamine agonist-resistant prolactinoma, mediating therapeutic effects by targeting multiple signaling pathways. Modulating miRNA expression may be a promising approach to treat dopamine agonist-resistant patients and improve prognosis.

NEUROENDOCRINOLOGY (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

The NETting of pituitary adenoma: a gland illusion

Ken K. Y. Ho et al.

PITUITARY (2022)

Add to Collection

Article Medicine, General & Internal

Classifying Pituitary Adenoma Invasiveness Based on Radiological, Surgical and Histological Features: A Retrospective Assessment of 903 Cases

Liang Lu et al.

Summary: Invasiveness is an important predictor of surgical outcome and long-term prognosis in patients with pituitary adenomas (PAs). This study assessed PA invasiveness through radiological, surgical, and histological perspectives and established a classification scheme to predict invasive behavior and poor prognosis. The study found that radiological and surgical invasiveness were better predictors of complete resection and recurrence/progression-free survival rates than histological invasiveness. Knosp grades with surgical invasiveness were also better predictors of prognosis compared to Knosp grades without surgical invasiveness. The classification schemes developed based on invasiveness and Knosp classification were found to be clinically valuable in predicting prognosis.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Review Medicine, General & Internal

Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions

Liang Lu et al.

Summary: This review summarizes the research progress on clinical and biological factors, including predictive factors and biomarkers, for recurrent pituitary adenomas. Comprehensive models and grading methods can be used to predict the prognosis of pituitary adenomas and may be beneficial for predicting recurrence.

DIAGNOSTICS (2022)

Add to Collection

Article Surgery

Clinicopathological Characteristics of Plurihormonal Pituitary Adenoma

Ruoyu Shi et al.

Summary: The pathogenesis of plurihormonal pituitary adenoma (PPA) remains unclear, and the diagnostic criteria are inconsistent. This study aimed to analyze the relationship between clinical and pathological characteristics in PPA. The results showed that PPA accounted for 13% of all pituitary cases recorded in the same period, with a higher prevalence in women. Most patients presented with one endocrine manifestation, and examination of hormones on tumor culture supernatant was helpful for its diagnosis.

FRONTIERS IN SURGERY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

A review of multiomics platforms in pituitary adenoma pathogenesis

Nikolaos Mouchtouris et al.

Summary: This article reviews the pathogenesis of pituitary adenomas and the recent advances in genomic analysis. It discusses key transcription factors and familial mutations associated with PitNETs, and explores the application of different genomic analysis methods.

FRONTIERS IN BIOSCIENCE-LANDMARK (2022)

Add to Collection

Article Endocrinology & Metabolism

Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors

Sylvia L. Asa

Summary: Detailed analysis of PitNETs has led to a formal classification system that reflects the lineage differentiation of non-tumor pituitary cells, and these tumors are now called PitNETs rather than adenomas. It is suggested to relinquish the term "pituitary carcinoma" for metastatic PitNETs that remain well differentiated, and to change the terminology used for tumors that are not terminally differentiated.

ENDOCRINE PATHOLOGY (2021)

Add to Collection

Review Clinical Neurology

Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section

Sam Ng et al.

Summary: Aggressive pituitary neuroendocrine tumors (APT) account for 10% of pituitary tumors and their management is rapidly evolving. The new term Pituitary neuroendocrine tumors (PitNet) reflects a shift towards a neuro-oncological-like approach. Treatment recommendations include surgery, temozolomide, local radiotherapy, and novel therapies such as VEGF-targeted therapies and immunotherapies.

ACTA NEUROCHIRURGICA (2021)

Add to Collection

Article Clinical Neurology

The Shape grading system: a classification for growth patterns of pituitary adenomas

Sven Berkmann et al.

Summary: This study evaluated the impact of different tumor shapes on gross total resection rates and outcomes in nonfunctioning pituitary adenomas, establishing a Shape grading system. Results showed that higher Shape grades were associated with lower GTR rates, larger tumor remnants, and the need for further treatments.

ACTA NEUROCHIRURGICA (2021)

Add to Collection

Review Pathology

Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification

Sylvia L. Asa et al.

Summary: The classification of adenohypophysial neoplasms as pituitary neuroendocrine tumors (PitNETs) reflects their characteristics as epithelial neuroendocrine neoplasms with a spectrum of clinical behaviors. Tumor growth and hormone hypersecretion can cause significant morbidity and mortality in patients. The intense study of PitNETs has provided important information about the importance of cellular differentiation in tumor prognosis.

MODERN PATHOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Ken Ho et al.

Summary: The debate over renaming pituitary neoplasms as PitNETs has sparked concerns among stakeholder groups. Experts recommend retaining the term adenoma and revisiting the topic as new evidence on pituitary neoplasm biology emerges.

JOURNAL OF THE ENDOCRINE SOCIETY (2021)

Add to Collection

Article Oncology

Pangenomic Classification of Pituitary Neuroendocrine Tumors

Mario Neou et al.

CANCER CELL (2020)

Add to Collection

Review Oncology

How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020

Jacqueline Trouillas et al.

CANCERS (2020)

Add to Collection

Article Endocrinology & Metabolism

Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors

John Turchini et al.

ENDOCRINE PATHOLOGY (2020)

Add to Collection

Review Clinical Neurology

Experience of trans-nasal endoscopic surgery for pituitary tumors in a single center in China: Surgical results in a cohort of 2032 patients, operated between 2006 and 2018

Chuzhong Li et al.

CLINICAL NEUROLOGY AND NEUROSURGERY (2020)

Add to Collection

Article Endocrinology & Metabolism

Surgical treatment of aggressive pituitary adenomas and pituitary carcinomas

Michael Buchfelder et al.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)

Add to Collection

Article Endocrinology & Metabolism

A tale of pituitary adenomas: to NET or not to NET Pituitary Society position statement

Ken K. Y. Ho et al.

PITUITARY (2019)

Add to Collection

Review Pathology

A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal

C. Villa et al.

VIRCHOWS ARCHIV (2019)

Add to Collection

Article Clinical Neurology

Proposal and Validation of a Simple Grading Scale (TRANSSPHER Grade) for Predicting Gross Total Resection of Nonfunctioning Pituitary Macroadenomas After Transsphenoidal Surgery

Michael A. Mooney et al.

OPERATIVE NEUROSURGERY (2019)

Add to Collection

Article Oncology

How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?

Maria Eugenia Torregrosa-Quesada et al.

CANCERS (2019)

Add to Collection

Review Oncology

New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors

Hiroshi Nishioka et al.

BRAIN TUMOR PATHOLOGY (2018)

Add to Collection

Article Oncology

Functions and Mechanisms of Tumor Necrosis Factor-α and Noncoding RNAs in Bone-Invasive Pituitary Adenomas

Haibo Zhu et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Multidisciplinary Sciences

Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours?

Araceli Garcia-Martinez et al.

PLOS ONE (2018)

Add to Collection

Article Pathology

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Guido Rindi et al.

MODERN PATHOLOGY (2018)

Add to Collection

Article Clinical Neurology

Invasive pituitary adenomas with gross total resection: The wait-and-see policy during postoperative management

Liang Lv et al.

JOURNAL OF CLINICAL NEUROSCIENCE (2018)

Add to Collection

Article Oncology

From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal

S. L. Asa et al.

ENDOCRINE-RELATED CANCER (2017)

Add to Collection

Article Multidisciplinary Sciences

Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas

Laura Sanchez-Tejada et al.

PLOS ONE (2017)

Add to Collection

Article Medical Laboratory Technology

Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma

William C. McDonald et al.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)

Add to Collection

Letter Clinical Neurology

A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours

Evelina Sjostedt et al.

ACTA NEUROPATHOLOGICA (2017)

Add to Collection

Review Endocrinology & Metabolism

Overview of the 2017 WHO Classification of Pituitary Tumors

Ozgur Mete et al.

ENDOCRINE PATHOLOGY (2017)

Add to Collection

Article Clinical Neurology

Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas

Edward F. Chang et al.

JOURNAL OF NEUROSURGERY (2008)

Add to Collection

Letter Clinical Neurology

The WHO classification of pituitary tumours: a combined neurosurgical and neuropathological view

R Fahlbusch et al.

ACTA NEUROPATHOLOGICA (2006)

Add to Collection

Article Endocrinology & Metabolism

DNA-flow cytometry of 207 pituitary adenomas: Ploidy, proliferation, and prognosis

ALO Machado et al.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2005)

Add to Collection

Article Endocrinology & Metabolism

The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'

P Nomikos et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.